Research Cluster
Gut Health, GI Function & Barrier Integrity Peptides
The gut is among the most peptide-dense tissues in the body. Secretin and CCK were the first hormones ever identified—discovered in 1902 and 1928 respectively—making this cluster a window into the history of endocrinology as well as current research frontiers. The approved compounds here are used diagnostically rather than therapeutically, which creates an important evidence interpretation question: a compound well-characterized in human physiology is not the same as a compound with proven therapeutic application.
BPC-157 is the most discussed peptide in community gut health contexts—and the one with the largest gap between preclinical data and human evidence. It was originally researched as a gastric protection compound. That origin story is well-documented. The human trial record for gut applications specifically is not.
Cluster at a Glance
7 compounds • 2 FDA-approved (diagnostic indications) • 2 Phase II/III clinical programs • 2 pilot/limited human data • 1 preclinical only
Approved Drug
Clinical Trials
Pilot / Human Data
Preclinical Only
Editorial note: Secretin and CCK are FDA-approved for diagnostic GI procedures, not for therapeutic GI health applications. A compound approved for a diagnostic indication has well-characterized human safety and physiological data—but that evidence does not automatically validate therapeutic use for gut health conditions. Both dimensions are documented separately for each compound.
How These Compounds Relate
The seven compounds in this cluster address gut health through four distinct mechanisms. Secretin and CCK are endogenous GI hormones that regulate digestive function—enzyme secretion, motility, bile flow, and satiety signaling—with the longest human research record of any compounds on this site. Ghrelin drives gastric motility via enteric GHS-R1a signaling, making it the most clinically advanced GI therapeutic candidate in the cluster. Larazotide targets the tight junction architecture of the gut epithelium itself—the physical barrier rather than the inflammatory response. BPC-157 and KPV address mucosal inflammation via different but partially overlapping cytokine suppression mechanisms. VIP operates as an enteric neurotransmitter with both motility and anti-inflammatory roles.
BPC-157 is the most community-discussed compound in this cluster for gut health applications, and its position here warrants explanation. Gut mucosal protection is BPC-157’s original research context—the compound was isolated from human gastric juice and the early research program focused on ulcer protection, NSAID gastropathy, and IBD models. The preclinical gut data is the most extensive of any BPC-157 application area. The human trial record for gut specifically is zero. That is an unusual gap—extensive preclinical data, robust community use, and no human GI trials. The gap exists, in part, because BPC-157 remains outside the conventional pharmaceutical development pipeline.
Larazotide and BPC-157 are frequently discussed together in gut barrier contexts, but they target different things. Larazotide acts specifically on tight junction proteins to prevent paracellular permeability. BPC-157 promotes mucosal angiogenesis, reduces local inflammation, and has broader cytoprotective effects across the GI tract. They are mechanistically complementary rather than redundant—and their evidence bases are radically different: Phase III clinical data vs. zero human GI trials.
VIP is the gut peptide whose cardiovascular and immune roles most clearly derive from its GI biology. It is an enteric nervous system neurotransmitter first—its immune and vascular effects are extensions of the same receptor signaling that governs gut motility and secretion. Understanding VIP as a gut peptide provides the mechanistic context for understanding its actions elsewhere.